Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2024

Dwyer Liam James, Singhal Nimit, Yu Bing, Kao Steven

Abstract excerpt

Adjuvant osimertinib represents a recent paradigm shift in the management of resected EGFR-mutated lung cancer. The optimal subsequent treatment of patients who relapse after completion of 3 years of adjuvant osimertinib is unknown. Here, we report two cases of complete response to osimertinib rechallenge after relapse from previous adjuvant osimertinib use, and a serial molecular panel exhibiting a lack of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Recurrence

Source

Identifiers

PMID: 38340108
DOI: 10.1016/j.jtho.2024.01.001

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.PMID 38340108Read ↗

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.Semantic proximity Read ↗

Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib.Semantic proximity Read ↗

Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.Semantic proximity Read ↗

EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.Semantic proximity Read ↗

Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients.Semantic proximity Read ↗

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.Semantic proximity Read ↗

Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Recurrent Escape from Osimertinib-Induced Senescence Promotes Genomic Instability Associated with Therapeutic ResistanceSemantic proximity Read ↗

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.Semantic proximity Read ↗

Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review.Semantic proximity Read ↗

Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.Semantic proximity Read ↗

Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.